The Rise of Alternative Telehealth: Joyous Reaches 90,000 Patients
San Francisco, Saturday, 23 May 2026.
Delivering over 17 million treatment doses since 2022, telehealth platform Joyous highlights a massive market shift toward accessible, alternative mental health therapies for depression and anxiety.
Scaling Alternative Psychiatric Care
On May 22, 2026, Joyous Public Benefit Corporation, a telehealth company headquartered in Foster City, California, announced a major operational milestone [1]. Since launching its platform in 2022 [alert! ‘The provided source does not specify the exact launch month in 2022’], the company has successfully delivered care to more than 90,000 patients across 28 U.S. states [1]. Over this four-year period, the platform has prescribed and distributed over 17 million individual doses of its treatment [1]. This rapid scaling underscores a significant transition within the healthcare sector, moving alternative psychiatric treatments from niche, in-person offerings to mainstream, accessible digital solutions [GPT].
Patient Demographics and Clinical Protocols
The demographic data emerging from Joyous’s patient base highlights a growing dissatisfaction with conventional psychiatric interventions [GPT]. According to the company, more than 76% of its users report having previously tried standard antidepressants, while over 83% are currently engaged in or have previously participated in traditional talk therapy [1]. Dr. Bobbi Leben, Co-Founder and Chief Medical Officer at Joyous, noted that an increasing number of patients are seeking these alternative therapies after spending years feeling underserved by traditional mental healthcare systems [1]. Clinical feedback from the platform indicates that patients are reporting meaningful improvements in their depression and anxiety symptoms [1].
Market Implications for Mental Health Telehealth
The sheer volume of the company’s output provides insight into patient retention and treatment frequency within the alternative psychiatric market. Based on the reported historical figures, the platform has administered an average of 188.889 doses per patient since 2022 [1]. As Dr. Leben observed, psychedelic treatments are rapidly transitioning beyond boutique, high-cost clinics into broader healthcare accessibility [1]. This shift not only democratizes access for patients navigating the ongoing mental health crisis but also signals a highly scalable model for healthcare executives and investors monitoring the evolution of the telehealth landscape [GPT].